-2.58 (-100.00%)
Upgrade to Real-Time
Premarket
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| VIVUS Inc | VVUS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 2.58 | 0.00 | 0.00 | 0.00 | 2.58 | 04:00:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 2.08 | 2.75 | 0.67 | 24.36% | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.00 | USD |
VIVUS Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 27.46M | 10.64M | $ -36.95M | -3.47 | -0.89 | 8.17M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 2.00 | 23.20% |
VIVUS News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VVUS Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.82 | 2.91 | 2.46 | 2.65 | 416,622 | -0.24 | -8.51% |
| 1 Month | 2.69 | 4.15 | 2.10 | 3.33 | 1,980,305 | -0.11 | -4.09% |
| 3 Months | 2.82 | 4.15 | 2.01 | 3.31 | 689,592 | -0.24 | -8.51% |
| 6 Months | 3.46 | 4.78 | 2.01 | 3.39 | 379,397 | -0.88 | -25.43% |
| 1 Year | 5.16 | 5.78 | 2.01 | 3.46 | 215,853 | -2.58 | -50.0% |
| 3 Years | 10.90 | 13.80 | 2.01 | 7.29 | 514,189 | -8.32 | -76.33% |
| 5 Years | 28.80 | 31.40 | 2.01 | 13.13 | 793,603 | -26.22 | -91.04% |
VIVUS Description
| VIVUS Inc is a US-based biopharmaceutical company engaged in developing and commercializing, next-generation therapies to address unmet medical needs in human health. Its commercial products include Qsymia, an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index; PANCREAZE which is a is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreatic glands, as well as other enzyme classes and Stendra/Spedra, which is an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. The company operates through the single segment of business being Development and commercialization of novel therapeutic products. |
